Blanco Maria-Jesus, La Daniel, Coughlin Quinn, Newman Caitlin A, Griffin Andrew M, Harrison Boyd L, Salituro Francesco G
Sage Therapeutics, Inc., 215 First Street, Cambridge, MA 02142, USA.
Sage Therapeutics, Inc., 215 First Street, Cambridge, MA 02142, USA.
Bioorg Med Chem Lett. 2018 Jan 15;28(2):61-70. doi: 10.1016/j.bmcl.2017.11.043. Epub 2017 Dec 2.
Endogenous and synthetic neuroactive steroids (NASs) or neurosteroids are effective modulators of multiple signaling pathways including receptors for the γ-aminobutyric acid A (GABA) and glutamate, in particular N-methyl-d-aspartate (NMDA). These receptors are the major inhibitory and excitatory neurotransmitters in the central nervous system (CNS), and there is growing evidence suggesting that dysregulation of neurosteroid production plays a role in numerous neurological disorders. The significant unmet medical need for treatment of CNS disorders has increased the interest for these types of compounds. In this review, we highlight recent progress in the clinical development of NAS drug candidates, in addition to preclinical breakthroughs in the identification of novel NASs, mainly for GABA and NMDA receptor modulation.
内源性和合成神经活性甾体(NASs)或神经甾体是多种信号通路的有效调节剂,这些信号通路包括γ-氨基丁酸A(GABA)和谷氨酸受体,特别是N-甲基-D-天冬氨酸(NMDA)受体。这些受体是中枢神经系统(CNS)中的主要抑制性和兴奋性神经递质,越来越多的证据表明神经甾体生成失调在众多神经疾病中起作用。治疗中枢神经系统疾病存在的重大未满足医疗需求增加了对这类化合物的兴趣。在本综述中,我们重点介绍了NAS候选药物临床开发的最新进展,以及在新型NASs鉴定方面的临床前突破,主要涉及GABA和NMDA受体调节。